|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Miscellaneous
DEFENCE THERAPEUTICS AND CQDM FUND THE DEVELOPMENT OF A NEW CANCER VACCINE PLATFORM
03.02.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
___________________________________________
CSE: DTC ... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Miscellaneous
Defence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES
31.01.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
______________________... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Miscellaneous
DEFENCE’S MELANOMA TARGETED VACCINE A1REPROGRAMMED MSC ARM CELL POTENCY VALIDATED
24.01.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
___________________________________________... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Conference
Defence Therapeutics Inc.: DEFENCE TO PRESENT AT THE 9TH ANNUAL IMMUNOONCOLOGY 360º SUMMIT IN NEWYORK FEBRUARY 710, 2023
23.01.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
CSE: DTC ... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Miscellaneous
Defence Therapeutics Inc.: DEFENCE ACCUMTM ACCEPTED US PATENT TO BOLSTER ITS VACCINE PLATFORM TECHNOLOGY IP
16.01.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
________________________________... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Miscellaneous
Defence Therapeutics Inc.: mRNA WITH DEFENCE’S ACCUMTM PROGRAM HAS BEEN INITIATED
10.01.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
____________________________________________________... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Defence Therapeutics Inc.
/ Key words: Miscellaneous
BREAKTHROUGH RESULTS: DEFENCE’S NOVEL ACCUTOXTM INTRANASAL REDUCED 50% OF CANCER NODULES ON ANIMALS WITH LUNG TUMORS
20.12.2022 / 15:25 CET/CEST
The issuer is solely responsible for the content of this announcement.
CSE: DTC FS... Lire le communiqué |
|
| |
|
| |
